2022
Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China—The China PEACE Retrospective Heart Failure Study
Yu Y, Guan W, Masoudi FA, Wang B, He G, Spertus JA, Lu Y, Krumholz HM, Li J. Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China—The China PEACE Retrospective Heart Failure Study. Journal Of The American Heart Association 2022, 11: e026300. PMID: 36172964, PMCID: PMC9673705, DOI: 10.1161/jaha.122.026300.Peer-Reviewed Original ResearchConceptsSpironolactone prescriptionSpironolactone useHeart failureMedian odds ratioIdeal patientAldosterone antagonistsHospital variationMedian rateReduced ejection fractionUse of spironolactoneMultivariable linear regression modelsHeart Failure StudyEjection fractionHospital characteristicsOdds ratioRepresentative cohortPatientsHospitalChinese hospitalsInappropriate usePrescriptionSpironolactoneSelect individualsAntagonistHigh rateUpdate on Renal Sympathetic Denervation for the Treatment of Hypertension
Rao A, Krishnan N. Update on Renal Sympathetic Denervation for the Treatment of Hypertension. Current Cardiology Reports 2022, 24: 1261-1271. PMID: 35895182, DOI: 10.1007/s11886-022-01753-x.Peer-Reviewed Original ResearchConceptsRenal sympathetic denervationTreatment of hypertensionRenal sympathetic nervesPathophysiology of hypertensionSympathetic denervationSympathetic nervesBlood pressureSafety of RSDRenal sympathetic nerve fibersAmbulatory blood pressure measurementsAntihypertensive drug useSham-controlled trialAdvanced kidney diseaseSympathetic nerve fibersLong-term efficacyPurpose of ReviewHypertensionBlood pressure measurementsExcellent safety profileModest treatment effectsLong-term safetyAntihypertensive medicationsAldosterone antagonistsCause mortalityNeurogenic controlResistant hypertensionCurrent Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION
Villa C, Auerbach SR, Bansal N, Birnbaum BF, Conway J, Esteso P, Gambetta K, Hall EK, Kaufman BD, Kirmani S, Lal AK, Martinez HR, Nandi D, O’Connor M, Parent JJ, Raucci FJ, Shih R, Shugh S, Soslow JH, Tunuguntla H, Wittlieb-Weber CA, Kinnett K, Cripe L. Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION. Pediatric Cardiology 2022, 43: 977-985. PMID: 35024902, PMCID: PMC8756173, DOI: 10.1007/s00246-021-02807-7.Peer-Reviewed Original ResearchConceptsVentricular assist deviceDuchenne muscular dystrophyHeart failureTherapeutic approachesAdvanced Cardiac Therapies Improving Outcomes NetworkDMD patientsBeta-blocker therapyMuscular dystrophyImplantable cardioverter defibrillatorAldosterone antagonistsSystolic dysfunctionCardiology providersHolter monitoringPrimary preventionDestination therapyPediatric cardiologistsCardiac careLeading causeOutcomes NetworkCardioverter defibrillatorCardiac diseaseClinical careMuscle therapyEnzyme inhibitorsCare practices
2020
The XPB Subunit of the TFIIH Complex Plays a Critical Role in HIV-1 Transcription, and XPB Inhibition by Spironolactone Prevents HIV-1 Reactivation from Latency
Mori L, Jenike K, Yeh YJ, Lacombe B, Li C, Getzler A, Mediouni S, Cameron M, Pipkin M, Ho YC, Ramirez BC, Valente S. The XPB Subunit of the TFIIH Complex Plays a Critical Role in HIV-1 Transcription, and XPB Inhibition by Spironolactone Prevents HIV-1 Reactivation from Latency. Journal Of Virology 2020, 95: 10.1128/jvi.01247-20. PMID: 33239456, PMCID: PMC7851559, DOI: 10.1128/jvi.01247-20.Peer-Reviewed Original ResearchAntiretroviral therapyHIV-1 transcriptionHIV transcriptionTreatment interruptionCell line modelsViral reservoirAbsence of ARTRapid viral reboundAcute HIV infectionHIV-1 reactivationChronic immune activationHIV-1 latencyLong-term treatmentHIV transcriptional regulationConcentrations of spironolactoneFunctional cure approachesCure approachesCellular mRNA expressionSP treatmentMechanism of actionHIV-1 genomeAldosterone antagonistsViral reboundFunctional cureHIV reactivation
2016
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition
Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation 2016, 133: 1115-1124. PMID: 26976916, PMCID: PMC4800749, DOI: 10.1161/circulationaha.115.018622.Peer-Reviewed Original ResearchMeSH KeywordsAbnormalities, Drug-InducedAminobutyratesAngioedemaAngiotensin Receptor AntagonistsBiphenyl CompoundsBradykininContraindicationsDrug CombinationsDrug CostsDrug SynergismEnalaprilEnzyme InhibitorsFemaleFollow-Up StudiesHeart FailureHumansHyperkalemiaHypertensionKidneyMulticenter Studies as TopicNatriuretic PeptidesNeprilysinPregnancyProdrugsProspective StudiesPyridinesRandomized Controlled Trials as TopicStroke VolumeTetrazolesThiazepinesValsartanConceptsValsartan/sacubitrilReduced ejection fractionHeart failureNatriuretic peptideEjection fractionN-terminal pro-brain natriuretic peptideNeprilysin inhibitor prodrug sacubitrilPro-brain natriuretic peptideAngiotensin receptor blocker valsartanAngiotensin receptor antagonismAngiotensin receptor blockersHeart Failure TrialReceptor blocker valsartanAngiotensin receptor antagonistsBrain natriuretic peptideOngoing clinical trialsMechanism of actionNeprilysin inhibitionAldosterone antagonistsAldosterone systemReceptor blockersBlood pressureFailure TrialPathophysiological mechanismsReceptor antagonismChallenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction
Jaiswal A, Chichra A, Nguyen VQ, Gadiraju TV, Le Jemtel TH. Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction. Current Heart Failure Reports 2016, 13: 30-36. PMID: 26780914, DOI: 10.1007/s11897-016-0278-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic obstructive pulmonary diseaseReduced ejection fractionObstructive pulmonary diseaseBeta blockersCOPD patientsEjection fractionHeart failurePulmonary diseasePrevalence of COPDManagement of patientsEvidence-based therapiesNumber of patientsHFrEF patientsAldosterone antagonistsEarly referralCOPD treatmentCommon symptomsTherapeutic managementClinical conundrumHFrEFPatientsClinical practiceEnzyme inhibitorsAdverse effectsDiseaseEffectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction
Wang T, Vora A, Peng S, Fonarow G, Das S, de Lemos J, Peterson E. Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. Journal Of The American Heart Association 2016, 5: e002612. PMID: 26796254, PMCID: PMC4859378, DOI: 10.1161/jaha.115.002612.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAge FactorsAgedAged, 80 and overDatabases, FactualDrug PrescriptionsDrug Utilization ReviewFemaleHeart FailureHumansHyperkalemiaMaleMedicareMineralocorticoid Receptor AntagonistsMyocardial InfarctionPractice Patterns, Physicians'RegistriesRisk AssessmentRisk FactorsSpironolactoneStroke VolumeTime FactorsTreatment OutcomeUnited StatesConceptsRisk of hyperkalemiaAcute renal failureAldosterone antagonistsAldosterone antagonist useAssociated with lower mortalityEjection fractionOlder MI patientsAntagonist useRenal failureRisk of acute renal failureAngiotensin-converting enzyme inhibitor/angiotensin receptor blockerMI patientsSymptomatic HF patientsLow ejection fractionAssociated with increased riskReduced ejection fractionInhibitor/angiotensin receptor blockerAldosterone antagonist therapyLower mortalityACTION Registry-GWTGPost-myocardial infarctionAcute myocardial infarctionAntagonist therapyReceptor blockersOlderly patients
2015
Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures
Allen LA, Fonarow GC, Liang L, Schulte PJ, Masoudi FA, Rumsfeld JS, Ho PM, Eapen ZJ, Hernandez AF, Heidenreich PA, Bhatt DL, Peterson ED, Krumholz HM. Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. Circulation 2015, 132: 1347-1353. PMID: 26316616, PMCID: PMC4941099, DOI: 10.1161/circulationaha.115.014281.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBody Mass IndexCardiovascular AgentsComorbidityContraindicationsCross-Sectional StudiesDrug HypersensitivityDrug PrescriptionsDrug SubstitutionDrug Therapy, CombinationDrug UtilizationEvidence-Based MedicineFemaleGuideline AdherenceHeart FailureHospitalsHumansMaleMedication AdherenceMiddle AgedPatient AdmissionPatient DischargePolypharmacyPractice Guidelines as TopicQuality Assurance, Health CareConceptsHF quality measuresHydralazine/isosorbide dinitrateAngiotensin receptor blockersMedication groupHeart failureAldosterone antagonistsReceptor blockersMedication regimenIsosorbide dinitrateNew medicationsΒ-blockersEnzyme inhibitorsGuideline-directed medical therapyInitiation of angiotensinPrimary discharge diagnosisQuarter of patientsPatient's medication regimenHospital quality measuresAdequate prescribingMedication initiationHospital dischargeHospital admissionMedical therapyGuideline recommendationsDischarge diagnosisNational Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient‐centered Evaluation Assessment of Cardiac Events (PEACE)‐Retrospective AMI Study, 2001, 2006, and 2011
Guan W, Murugiah K, Downing N, Li J, Wang Q, Ross JS, Desai NR, Masoudi FA, Spertus JA, Li X, Krumholz HM, Jiang L, Group T. National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient‐centered Evaluation Assessment of Cardiac Events (PEACE)‐Retrospective AMI Study, 2001, 2006, and 2011. Journal Of The American Heart Association 2015, 4: e001718. PMID: 26071031, PMCID: PMC4599529, DOI: 10.1161/jaha.114.001718.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionHeart failureMyocardial infarctionUse of spironolactoneNational practice patternsProportion of patientsAssessment of eligibilitySpironolactone useAldosterone antagonistsSystolic dysfunctionCardiac eventsAMI patientsChina PatientPatient eligibilityPatient groupUnknown indicationPractice patternsIdeal patientPatientsSpironolactoneEligibilityAppropriate useInfarctionDiabetesNational quality assessment
2013
Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation
Hess PL, Kim S, Piccini JP, Allen LA, Ansell JE, Chang P, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Fonarow GC. Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation. The American Journal Of Medicine 2013, 126: 625-632.e1. PMID: 23787195, PMCID: PMC4037289, DOI: 10.1016/j.amjmed.2013.01.037.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntihypertensive AgentsAtrial FibrillationCardiovascular DiseasesComorbidityDefibrillators, ImplantableEvidence-Based PracticeFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLogistic ModelsMalePlatelet Aggregation InhibitorsPractice Guidelines as TopicRegistriesRisk FactorsConceptsCardiovascular comorbid conditionsEvidence-based therapiesAtrial fibrillationRisk factorsComorbid conditionsEvidence-based therapy useMore evidence-based therapiesGuideline-recommended therapiesAngiotensin receptor blockersAntiarrhythmic drug therapyCardiovascular risk factorsPeripheral vascular diseaseMinority of patientsCoronary artery diseaseMultivariable logistic regressionUS national registryAngiotensin-converting enzymeAldosterone antagonistsComorbid illnessesReceptor blockersComorbid diseasesAntiplatelet agentsArtery diseaseDiabetes mellitusHeart failureTreatment of Severe Metabolic Alkalosis in a Patient With Congestive Heart Failure
Peixoto AJ, Alpern RJ. Treatment of Severe Metabolic Alkalosis in a Patient With Congestive Heart Failure. American Journal Of Kidney Diseases 2013, 61: 822-827. PMID: 23481366, DOI: 10.1053/j.ajkd.2012.10.028.Peer-Reviewed Original ResearchConceptsCongestive heart failureHeart failureMetabolic alkalosisLow bicarbonate dialysisRenal bicarbonate excretionRenin-angiotensin systemSevere metabolic alkalosisDistal sodium deliveryCommon acid-base disorderAcid-base disordersDiuretic regimenDiuretic therapyAldosterone antagonistsNeurohormonal activationCirculatory failureBicarbonate excretionKidney failurePotassium repletionSodium deliveryBase excessUrine acidificationAppropriate managementAlkalosisDisease statesBicarbonate retention
2012
Temporal Trends and Predictors in the Use of Aldosterone Antagonists Post-Acute Myocardial Infarction
Rassi A, Cavender M, Fonarow G, Cannon C, Hernandez A, Peterson E, Peacock W, Laskey W, Rosas S, Zhao X, Schwamm L, Bhatt D. Temporal Trends and Predictors in the Use of Aldosterone Antagonists Post-Acute Myocardial Infarction. Journal Of The American College Of Cardiology 2012, 61: 35-40. PMID: 23137936, DOI: 10.1016/j.jacc.2012.08.1019.Peer-Reviewed Original ResearchMeSH KeywordsAgedDiabetes MellitusDrug PrescriptionsDrug UtilizationFemaleGuideline AdherenceHeart FailureHospital Bed CapacityHumansKidney DiseasesMaleMineralocorticoid Receptor AntagonistsMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationPatient DischargePractice Guidelines as TopicRegistriesSmokingStroke VolumeUnited StatesConceptsPost-acute myocardial infarctionAldosterone antagonist useAldosterone antagonist therapyAldosterone antagonistsEjection fractionAntagonist useEligible patientsAntagonist therapyHospital dischargeHeart failureMyocardial infarctionActual prescribing patternsGuideline-based therapyAbsence of contraindicationsHistory of diabetesPost-AMI patientsHigher ejection fractionAmerican Heart AssociationLarger hospital sizeCoronary revascularizationPrescribing patternsAMI patientsKidney dysfunctionPost-AMITobacco abuse
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply